go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Alliance Pharmaceuticals Ireland

Alliance Pharmaceuticals Ireland
United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
Telephone: + 44 (0)1249 466966
Fax: +44 (0)1249 466 977
Medical Information e-mail: medinfo@alliancepharma.co.uk


Summary of Product Characteristics last updated on medicines.ie: 04/05/2011
SPC Naseptin Nasal Cream

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipients
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Naseptin 0.1% & 0.5% w/w Nasal Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Chlorhexidine dihydrochloride0.1 %w/w
Neomycin Sulphate0.5 %w/w (3250 IU/g)

Excipients: Contains 8% w/w (80mg/g) cetostearyl alcohol

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Nasal cream.

White, non-greasy, water-miscible nasal cream.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Naseptin is an antimicrobial cream intended for application to the nares. It is used for eradicating staphylococcal infections, and carriage in the nose.


Go to top of the page
4.2 Posology and method of administration

A small amount of Naseptin is placed on the little finger and applied to the inside of each nostril.

For prophylaxis: Naseptin is applied as above, twice daily, to prevent patients from becoming carriers and to inhibit the dispersion of staphylococci.

For eradication of infection: Naseptin is applied four times daily for 10 days to eliminate organisms from the nares.


Go to top of the page
4.3 Contraindications

Hypersensitivity to chlorhexidine and neomycin or to any of the excipients.

Some patients have shown a hypersensitivity reaction to neomycin or chlorhexidine, although such reactions are extremely rare.


Go to top of the page
4.4 Special warnings and precautions for use

For nasal application only. Keep out of the eyes and ears.

Topical application of neomycin preparations can cause skin sensitisation in a small number of patients. Prolonged use of neomycin can lead to ototoxicity and nephrotoxicity.

If no improvement occurs or there is aggravation, stop use and consult the physician.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

See section 6.2.


Go to top of the page
4.6 Pregnancy and lactation

No special precautions are necessary.


Go to top of the page
4.7 Effects on ability to drive and use machines

No precautions are necessary.


Go to top of the page
4.8 Undesirable effects

Local irritation and hypersensitivity can occasionally occur.

Prolonged use may lead to skin sensitisation to neomycin.

Anaphylaxis to chlorhexidine has been reported rarely.


Go to top of the page
4.9 Overdose

Accidental ingestion

Accidental ingestion of the contents of a Naseptin tube is not likely to have any adverse effect on the patient.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other antibiotics for topical use

ATC code: D06AX

Chlorhexidine is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is inactive against bacterial spores except at elevated temperatures.

Neomycin is a rapidly bactericidal aminoglycoside antibiotic effective against Gram positive organisms including staphylococci and a wide range of Gram negative organisms. Strains of Pseudomonas aeruginosa are resistant to neomycin, as are fungi and viruses.


Go to top of the page
5.2 Pharmacokinetic properties

Because of its cationic nature, chlorhexidine binds strongly to skin, mucosa and other tissues and is thus very poorly absorbed. No detectable blood levels have been found in man following oral use and percutaneous absorption, if it occurs at all, is insignificant.

Neomycin is either not absorbed or is absorbed only minimally through intact skin. Any neomycin which is absorbed will be rapidly excreted by the kidneys in an unchanged state.


Go to top of the page
5.3 Preclinical safety data

Chlorhexidine and neomycin are drugs on which extensive clinical experience has been obtained. Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Cetostearyl alcohol

Medium-chain triglycerides

Cetostearyl alcohol/ethylene oxide condensate

Purified water


Go to top of the page
6.2 Incompatibilities

Chlorhexidine is incompatible with soap and other anionic agents.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30ºC. Keep the tube tightly closed. Keep the tube in the outer carton.


Go to top of the page
6.5 Nature and contents of container

Internally lacquered aluminium tube (15g).


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Alliance Pharmaceuticals Limited

Avonbridge House

2 Bath Road

Chippenham

Wiltshire SN15 2BB

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 943/2/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 April 1983

Date of last renewal: 01 April 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

March 2011



Link to this document from your website:
http://www.medicines.ie/medicine/4834/SPC/Naseptin+Nasal+Cream/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Neomycin Sulphate
   Chlorhexidine Dihydrochloride

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo